Subsequent Acquisition

12 Months Ended

Dec. 31, 2011

Subsequent Acquisition [Abstract]

Subsequent Acquisition

Note 22 - Subsequent Acquisition:

During the three months ended June 30, 2011, we entered into a definitive agreement to purchase privately-held Edict Pharmaceuticals Private Limited (referred to as "Edict" or "Edict Pharmaceuticals"), a Chennai, India-based developer and manufacturer of generic pharmaceuticals, for up to $37.6 million in cash and our repayment of certain additional pre-close indebtedness. As of December 31, 2011, the closing of the acquisition was still pending. This transaction was completed on February 17, 2012. The acquisition will be accounted for as a business combination under the guidance of FASB ASC 805 Business Combinations, however our initial accounting for this transaction is currently incomplete. Therefore, the required disclosures associated with a business combination are not available as of the date of this Form 10-K. The operating results of Edict will be included in our consolidated financial results from the date of acquisition as part of the Par Pharmaceutical segment. We funded the purchase from cash on hand.